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Abstract 
Introduction: There is a shortage of validated instruments to estimate disease 
progression in frontotemporal dementia (FTD). Objectives: To evaluate the ability of 
the FTD Rating Scale (FTD-FRS) to detect functional and behavioral changes in 
patients diagnosed with the behavioral variant of FTD (bvFTD), primary progressive 
aphasia (PPA) and Alzheimer disease (AD) after 12 months of the initial evaluation, 
compared to the Clinical Dementia Rating scale - frontotemporal lobar 
degeneration (CDR-FTLD) and the original Clinical Dementia Rating scale (CDR). 
Methods: The sample consisted of 70 individuals, aged 40+ years, with at least two 
years of schooling, 31 with the diagnosis of bvFTD, 12 with PPA (8 with semantic 
variant and 4 with non-fluent variant) and 27 with AD. The FTD-FRS, the CDR and the 
two additional CDR-FTLD items were completed by a clinician, based on the 
information provided by the caregiver with frequent contact with the patient. The 
Addenbrooke’s Cognitive Examination-Revised (ACE-R) was completed by patients. 
After 12 months, the same protocol was applied. Results: The FTD-FRS, CDR-FTLD 
and CDR detected significant decline after 12 months in the three clinical groups 
(exception: FTD-FRS for PPA). The CDR was less sensitive to severe disease stages. 
Conclusions: The FTD-FRS and the CDR-FTLD are especially useful tools for 
dementia staging in AD and in the FTD spectrum.  
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Introduction  
 
Staging dementia is a vital aspect for the proper clinical management of affected 
patients. Staging may guide personalized care, as care needs change as the disease 
progresses. In addition, staging scales may document the impact of drugs with the 
potential to change the course of the underlying disorder. 
Dementia staging scales usually assess typical symptoms of Alzheimer disease 
(AD). For instance, the Clinical Dementia Rating scale (CDR) has been used for more 
than two decades to document disease progression in AD1–3. Although the CDR has 
brought significant contributions to the field, it has been found to be a limited staging 
tool for non-AD dementias. For example, the CDR failed to identify the severe stages of 
the behavioral variant of frontotemporal dementia (bvFTD), most likely because it does 
not include items probing the most frequent behavioral and functional symptoms within 
the spectrum of this disorder4. Other studies have shown that the CDR may not be able 
to identify decline in FTD 5-6. 
Given the need of instruments for FTD staging, Mioshi et al.4 developed and 
validated the FTD Rating Scale (FTD-FRS). The FTD-FRS was structured using items 
from the Disability Assessment Scale (DAD)7 and the Cambridge Behavioral Inventory 
(CBI)8, 9, resulting in a 75-item questionnaire covering symptoms of behavioral 
disorders and functional disability. The new instrument was applied in a sample of 77 
patients with FTD (bvFTD = 29; semantic variant Primary Progressive Aphasia - svPPA 
= 28; agrammatic variant - aPPA = 20), matched for age and duration of symptoms. 
After psychometric and construct validity analyses, the scale was reduced to 30 items1. 
In a 12-month follow up, the FTD-FRS was able to detect decline in all three FTD 
variants, with faster decline for patients with bvFTD. 
The FTD-FRS has been translated and validated in other countries 5, 6. Schubert 
et al.  10 have replicated the finding that patients with bvFTD show faster decline in the 
FTD-FRS, compared to other clinical groups, and suggested that neuropsychological 
evaluation alone may not distinguish the distinct trajectories of bvFTD and AD patients. 
Other scales have been used to measure disease progression in FTD dementia 
subtypes. O'Connor et al. 11 reported higher functional decline among patients with 
bvFTD when compared to svPPA using the CBI and the DAD. Compared to the 
baseline, patients with bvFTD had greater functional decline than patients with svPPA. 
Also, in 12 months, patients with bvFTD decreased in disinhibition and stereotyped 
behaviors and had higher appetite changes, whereas patients with svPPA had higher 
stereotyped behaviors. 
In 2008, the CDR was extended to include typical symptoms of FTD. The CDR-
FTLD scale, as it is known, seems to be effective in staging patients in the FTD 
spectrum12, 13. No previous study has compared directly the ability of different staging 
scales to capture disease progression in FTD and AD14.  
Therefore, in the present study we aimed to investigate rates of disease 
progression in FTD and AD using three staging tools: the FTD-FRS, CDR-FTLD sum 
of boxes (CDR-FTLD- SOB) and the CDR sum of boxes (CDR- SOB), over a 12-month 
follow-up study. We hypothesized that the FTD-FRS and the CDR-FTLD would detect 
significant changes in the follow-up assessment of FTD patients that would not be 
detected by the CDR, as the two former scales include questions regarding specific FTD 
symptoms. As an additional aim, we tested whether global cognitive scales could also 
detect change over the 12-month follow-up. 
 
Methods 
 
Participants 
 
Databases from specialized university-based Neurology outpatient services were 
queried, and patients and their family caregivers were invited to take part in the study. 
Three specialist centres in Brazil were involved: Cognitive and Behavioral Neurology 
Group (GNCC-SP), of the University of São Paulo; Cognitive and Behavioral 
Neurology Group (GNCC-MG) of the Federal University of Minas Gerais and the 
outpatient services of the Department of Neurology of the State University of Campinas 
(UNICAMP).  
A total of 70 individuals, comprising 31 diagnosed with bvFTD, 12 with PPA (8 
semantic variant and 4 non-fluent variant), and 27 with AD were included in the study. 
Formal and informal caregivers who had frequent contact with the patient were 
interviewed in regard to the patient´s symptoms (see Supplementary Table 1 for the 
sociodemographic characteristics of the caregivers). 
The FTD-FRS, the CDR and the CDR-FTLD items were filled out by the 
clinician based on the information provided by the caregivers for each item during a 
clinical interview. The diagnosis of dementia was given by neurologists, based on 
clinical and cognitive assessments, laboratory and neuroimaging exams. Dementia was 
diagnosed based on the criteria from the Diagnostic and Statistical Manual 5th Edition 
(DSM-V)15. International diagnostic criteria were employed for diagnosing probable 
bvFTD16. The National Institute on Aging- Alzheimer's Association- NIA/AA criteria 
were used for AD diagnosis17, 18. The most recent PPA criteria were used for diagnosing 
the semantic and non-fluent variants of FTD19. 
Inclusion criteria for patients were age >40 years, education >2 years, CDR=0.5, 
1 or 2, and presence of a caregiver who was involved in the daily routine of the patient; 
spending more than 8 hours/day with the patient. Individuals presenting with visual, 
auditory or motor deficits preventing them from understanding instructions or 
performing cognitive tasks; individuals with other uncontrolled clinical diseases (such 
as hypertension and diabetes); serious and debilitating psychiatric disorders such as 
major depression, schizophrenia, bipolar disorder; patients using unstable psychotropic 
drugs, clinical evidence or neuroimaging exam findings suggestive of vascular 
problems; dementias or etiologies other than FTD or AD, were excluded from the 
sample. 
 
Instruments 
 
Demographic Information 
 
Sociodemographic and clinical data, including age, income, years of education, 
marital status, general health status, comorbidities and use of medications was collected 
via questionnaires completed by caregivers.  
 
Cognitive assessment 
 
The Mini Mental State Exam (MMSE)20 was administered at baseline and 
follow up 21. MMSE maximum score is 30. The Addenbrooke´s Cognitive Examination-
Revised (ACE-R)22, 23, 24 was also administered at baseline and follow-up. The ACE-R 
maximum score is 100 points and the cognitive domains evaluated include: attention 
and orientation (18/100), memory (26/100), verbal fluency (14/100), language (26/100) 
and visuospatial ability (16/100)23. 
 
Dementia staging scales 
 
The CDR9, 25 assesses the domains of memory, orientation, judgment and 
problem solving, community affairs, home and hobbies, and personal care. The CDR-
FTLD is an expanded version for the CDR scale and it assesses two additional domains: 
language and behavior12, which are tailored for FTD symptoms. During data collection, 
the clinician makes an evaluation of each domain with scores ranging from 0, 0.5, 1, 2 
and 3, and a general evaluation of the dementia stage is made using this same gradation. 
In the present study, the CDR and the CDR-FTLD scores refer to the sum of the scores 
of each domain, sum of boxes, that ranges from 0 to 18 for the CDR and from 0 to 24 
for the CDR-FTLD. The CDR and CDR-FTLD scores will refer to the sum of boxes of 
each scale in the remaining parts of this study, unless stated otherwise. We chose to 
analyze the sum of boxes, instead of the global categorical score, because the sum of 
boxes might better reflect minor changes between the two assessment points.   
The FTD-FRS detects dementia severity through a combination of decline in 
functional abilities (e.g. ability to use a telephone, ability to manage medications, eating 
behaviors), as well as neuropsychiatric symptomatology (e.g. loss of affection, 
impulsivity) 1, 6. The answer options for each question are: always = 0, sometimes = 0 
and never = 1. The score for each item is added and divided by the number of questions 
(ranging from 0 to 30) answered by the interviewee, thus generating a percentage that is 
subsequently converted to a logarithmic score ranging from 5.39 (normal) to - 6.66 
severe/advanced, available in a table provided by the authors who validated the scale1, 6.  
 
Ethics 
An informed consent form was filled out by caregivers. This study was approved 
by the Ethics Committee from the University of São Paulo School of Medicine 
(protocol number 311.601). The study was conducted in compliance with international 
ethical standards expressed in the Declaration of Helsinki. 
 
Data Analysis 
 
The Kolmogorov-Smirnov tests indicated that the MMSE, ACE-R, FTD-FRS, 
CDR-FTLD and CDR did not follow a normal distribution. In the cross-sectional 
analysis at baseline, the Chi-square test was used to compare the categorical variables 
and the Kruskall-Wallis test was used to compare the continuous variables among the 
three diagnostic groups. Multiple comparisons were conducted when the Kruskall-
Wallis test was significant. 
In the longitudinal analyses, we used the Wilcoxon signed-rank test (Z statistic) to 
compare the means of the ACE-R, MMSE, CDR-FTLD and CDR, and the FTD-FRS 
logarithmic scores. This statistical test evaluates if the means of the studied sample 
differ between baseline and follow-up, and the higher the Z value, the greater the 
difference between the mean scores in the two assessments. 
The data were entered in the Epidata Program version 3.1. to create the database 
mask. For statistical analyses, SPSS v.17.0 and Statistica v. 7.0 were used. The 
significance level adopted for the statistical tests was 5%, with p-value <0.05. 
 
Results 
 
Table 1 shows the sociodemographic characteristics of the sample at baseline. 
Participants with AD were significantly older than those with bvFTD and PPA, and AD 
patients had fewer years of formal education than those with PPA. The clinical groups 
were statistically equivalent as to the categorical classification of the CDR.  
 
 
Insert Table 1  
 
Table 2 shows results for the cognitive scales (ACE-R and MMSE) and for the 
three staging scales (FTD-FRS, CDR-FTLD, CDR) at baseline and follow-up. 
Cognitive and staging scales documented significant decline after 12 months. One AD 
patient was lost to follow-up. The FTD-FRS did not detect significant decline in the 
PPA group (Table 2 and Figure 1). Effect size analyses suggested higher decline among 
bvFTD and PPA patients than AD (with the exception of the CDR-FTLD score). 
 
Insert Table 2 
Insert Figure 1 
 
For illustrative purposes, Figure 2 shows the percentage of patients in each 
severity level of the staging tools at baseline and 12-month follow up for each 
diagnostic group. Figure 2 indicates that a large percentage of participants are classified 
as severe or very severe by the FTD-FRS and the CDR-FTLD. In contrast, when the 
original CDR score is assigned a severity label, a smaller percentage of patients fall into 
these categories (i.e., a larger percentage are categorized as moderate or mild). 
Supplementary Tables 2 to 5 report the corresponding CDR-FTLD scores at each FTD-
FRS severity level, for baseline and follow-up, for the total sample and for each 
diagnostic group.    
 
Insert Figure 2 
 
Discussion 
The present study aimed to directly compare three staging scales in their ability 
to detect disease progression in bvFTD, PPA and AD. We observed that all three scales, 
as well as the MMSE and the ACE-R, documented disease progression in the 12-month 
follow up. The CDR seemed less sensitive to the severe stages of the diseases (Figure 
2). The study presents new and relevant information as direct comparisons of staging 
scales in longitudinal studies are rare. 
Staging scales for dementia, such as the CDR, are considered robust assessments 
to characterize and track the course of AD symptoms compared to measures of 
functional or cognitive performance25. However, there are concerns whether the CDR 
may be used to stage FTD1. In the present study, the FTD-FRS and the CDR-FTLD 
seemed to detect the more severe stages of bvFTD, as a relevant proportion of patients 
that were classified as very mild and mild by the CDR were classified as being in the 
moderate or severe stages, according to the FTD-specific scales (FTD-FRS, CDR-
FTLD).  
These findings are in line with Mioshi et al.4 and Turró-Garriga et al. 5 who also 
identified a larger number of patients in more severe dementia stages using the FTD-
FRS, compared to the CDR. Lima-Silva et al. 6, in a cross-sectional study, observed that 
a sample of 12 patients with bvFTD, classified by the CDR as mild, were classified by 
the FTD-FRS as moderate or severe. 
Although clinical groups in the present study did not differ according to CDR 
scores at baseline, FTD-FRS scores suggested patients with bvFTD were in more severe 
disease stages compared to the other diagnostic groups. These findings are in agreement 
with previous studies, which used the DAD and FTD-FRS, respectively7, 8. Deutsch et 
al. 27, in a cross-sectional study with 20 patients with bvFTD and 20 with AD, observed 
that the bvFTD group had greater functional and cognitive impairment, greater presence 
of neuropsychiatric symptoms, and a higher level of disease severity assessed by the 
CDR-FLTD. These findings suggest that scales including FTD specific symptoms may 
better characterize disease stage in dementias of the FTD spectrum.  
It is necessary to note that the assessment strategy of each instrument may have 
had an influence on present findings. The CDR and the CDR-FTLD offer a response 
anchor with five options (0, 0.5, 1, 2, 3), whereas the FTD-FRS offers only three 
options (always = 0, sometimes = 0 and never = 1), and the 0 score indicates that the 
symptom may be present with varying frequencies. Therefore, the FTD-FRS may 
overestimate mild symptoms and generate a higher percentage of more severe cases. 
These differences among assessment tools highlight the value of follow-up data, as they 
may elucidate how each instrument may capture change. Effect size analyses may also 
add relevant information, as seen in Table 2. 
The follow-up analyses revealed that the three staging scales (FTD-FRS, CDR-
FTLD, CDR) showed significant decline from baseline in all diagnostic groups. The 
FTD-FRS failed to identify significant disease progression in PPA, but the results were 
close to statistical significance. This may be due to the fact that the PPA sample was 
smaller, thus reducing statistical power. Alternatively, this finding may be related to the 
fact that the FTD-FRS does not include items probing specifically on language 
difficulties. However, the PPA group showed, from baseline to follow up, a score 
change in this scale that approached significance in mean and SE, respectively, -0.30 
(0.89) and -1.61 (0.70), with a large effect size, indicating an important decline. 
Mioshi et al. 4, using the CDR and the FTD-FRS, concluded that the FTD-FRS 
was more sensitive to assess the clinical changes in patients with FTD 4. In the follow-
up data of the present study, according to z-score values (Figure 1), patients with 
bvFTD seemed to decline more significantly, than patients with PPA and AD, in both 
FTD-FRS and CDR-FTLD. Our findings corroborate the findings from O'Connor et al. 
8, with a four-year follow-up of a sample of patients diagnosed with FTD variants, when 
the bvFTD group presented the highest rate of decline in the DAD 8. In general, 
longitudinal studies with patients with FTD are still scarce and have reached different 
conclusions as to the rate of decline 27–30. 
Our study confirms that bvFTD may progress at a faster pace than other 
dementias, in agreement with Mioshi et al. 32 and Wicklund et al. 33. A recent study 
characterized the longitudinal changes in 161 patients with bvFTD (n = 77) and the 
semantic (n = 45) and non-fluent (n = 39) variants of PPA. Declines in functional and 
neuropsychological measures, as well as frontal and temporal cortical volumes and 
white matter microstructure, were detected in all groups. Changes in imaging 
parameters were significantly correlated with change, and explained a substantial 
portion of variance, in most clinical measures34. The slower progression in semantic 
variant PPA, also observed in our study (tentatively due to small sample size), is in line 
with the prolonged survival shown in a consecutive series of 100 patients35. 
The present analyses suggest that cognitive tests can also detect disease 
progression. Our findings support Schubert et al. 7, who found decline in cognitive and 
staging scores of patients with bvFTD and AD at the three-year follow-up evaluation. 
Follow-up studies focusing on cognitive scores have been conducted in small samples 
using the MMSE 36,37 and  have suggested that in one year there was significant decline 
in MMSE scores in patients with FTD.  
Among the limitations of the study, we shall mention the small sample of 
patients with PPA, In addition, we highlight that the fact that the PPA variants were not 
separated in the analyses is an important limitation, as each variant has particular 
clinical, genetic markers and progression rates, according to previous literature data19. 
Therefore, future studies on clinical trajectories in PPA should include larger samples of 
each variant. Also, a 12-month follow up may be too short for studying dementia 
progression, although the investigated tools were able to detect significant change in 
this period.   
In summing up, we conclude that the FTD-FRS, CDR-FTLD and the CDR are 
useful tools in dementia management. Although cognitive tests were able to capture 
change in 12 months, staging based on cognitive scores may be limited, as they are 
heavily dependent on language skills. In addition, cognitive cutoff scores may be 
inadequate for staging dementia in developing countries, because of the influence of 
education, which may vary greatly. Therefore, scales such as the FTD-FRS may provide 
a better understanding of progression in FTD by showing which skills are impaired at 
the beginning and in later stages of the disorder. This information may aid in care 
management and rehabilitation efforts.  
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Table 1. Sociodemographic description of the sample stratified by clinical group at 
baseline. 
Variables 
bvFTD (n=31) PPA (n=12) AD (n=27) 
p-value 
Mean 
Standard 
Error 
Mean 
Standard 
Error 
Mean 
Standard 
Error 
Age (50-87 years) 66.94 (1.66) † 61.42 (1.69) † 74.15 (1.77) #‡ <0,001* 
Schooling (2-21 years) 11.74 (0.82) 14.33 (1.27) † 9.26 (0.86) ‡ 0.007 * 
Sex (% women) 41.94 41.67 62.96 0.228** 
Marital status  
(% married) 
51.60‡ 55.60#† 100‡ 0.012** 
CDR category (%)    0.091** 
0.0 0.00 8.33 3.70  
0.5 25.81 0.00 40.74  
1.0 54.84 66.67 44.44  
2.0 19.35 25.00 11.11  
CDR – sum of boxes 5.90 (0.50) 7.04 (0.97) 5.74 0.45 0.432* 
Note: bvFTD = behavioral variant frontotemporal dementia, PPA = primary progressive 
aphasia, AD = Alzheimer disease, CDR = Clinical Dementia Rating scale.  
*Kruskal-Wallis test: H ( 2, N= 70) =1,677237 p =0,432. 
**Results of χ2 test.  
#Differ from bvFTD. 
‡Differ from PPA. 
†Differ from AD. 
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Figure 1. Changes in the FTD-FRS, CDR-FTLD sum of boxes and CDR sum of boxes 
for the clinical groups at baseline and 12-month follow up. 
Table 2. Means and standard errors for cognitive and staging scales at baseline and 12-month follow-up. 
Variables bvFTD (n=31) PPA (n=12) AD (n=27) 
Baseline Follow-up Baseline Follow-up Baseline Follow-up 
ACE-R 71.71 (3.09) 68.70 (2.80) 65.75 (4.53) 65.50 (4.22) 67.09 (2.39) 66.64 (2.21) 
 Z=3.180 p=0.001 Z=1.992 p=0.046 Z=2.023 p =0.043 
 Effect size= 0.571 Effect size=0.575 Effect size=0.389 
MMSE 23.61 (0.94) 22.13 (0.89) 23.75 (1.35) 21.80 (0.95) 23.09 (0.72) 22.64 (0.75) 
 Z=2.803 p=0.005 Z=2.201 p=0.028 Z=2.028 p=0.042 
 Effect size=0.503 Effect size=0.635 Effect size=0.390 
FTD-FRS -1.99 (0.50) -2.65 (0.45) -0.30 (0.89) -1.61 (0.70) 0.07 (0.37) -016 (0.33) 
 Z=2.856 p=0.004 Z=1.820 p=0.069 Z=2.201 p=0.028 
 Effect size=0.513 Effect size=0.525 Effect size=0.424 
CDR-FTLD 8.06 (0.65) 9.00 (0.59) 9.96 (1.22) 10.38 (1.16) 7.02 (0.62) 7.81 (0.56) 
 Z=3.408 p=0.001 Z=2.023 p=0.043 Z=3.180 p=0.001 
 Effect size=0.612 Effect size=0.584 Effect size=0.612 
CDR 5.90 (0.50) 6.42 (0.44) 7.04 (0.97) 7.21 (0.95) 5.74 (0.45) 6.07 (0.41) 
 Z=3.059 p=0.002 Z=1.826 p=0.068 Z=2.665 p=0.007 
 Effect size=0.549 Effect size=0.527 Effect size= 0.513 
Note: Z and p-level of Wilcoxon Matched Pairs Test.  
Effect Size: According to Cohen’s classification of effect sizes: 0.1 (small effect), 0.3 (moderate effect) and 0.5 and above (large effect).  
bvFTD = behavioral variant frontotemporal dementia, PPA = primary progressive aphasia, AD = Alzheimer disease, 
ACE-R/Total indicates Addenbrooke cognitive examination-revised; MMSE, mini-mental state exam; FTD-FRS, frontotemporal dementia rating 
scale; CDR-FTLD=clinical dementia rating scale for frontotemporal lobar degeneration; CDR = Clinical Dementia Rating scale.  
 
 
 
 
Figure 2. Proportion of patients in each severity stage for frontotemporal dementia (bvFTD), Alzheimer's disease (AD) and primary progressive 
aphasia (PPA) according to Frontotemporal Dementia Rating Scale (FTD-FRS) and to Clinical Dementia Rating Scale (CDR-SOB) and CDR-
FTLD. 
Supplementary Table 1. Sociodemographic description of the caregiver sample stratified 
by clinical group at baseline. 
Variables 
bvFTD (n=31) PPA (n=12) AD (n=27)  
n/Mean %/SD n/Mean %/SD n/Mean %/SD p-value 
Age 54.61 10.54 51.75 19.01 50.18 17.38 0.671* 
Schooling 13.48 3.81 13.17 2.48 13.18 3.65 0.884* 
Sex (n, % women) 27 87.1 9 75.0 20 71.4 0.873** 
Relationship         
Spouse (n, %) 16 51.6 6 50.0 10 35.7 0.639** 
Son 11 35.5 5 41.7 12 42.9  
Other 4 12.9 1 8.3 6 21.4  
Hours caring/day 14.19 8.51 15.67 6.90 13.00 7.45 0.414* 
Note. bvFTD = behavioral variant frontotemporal dementia, PPA = primary progressive 
aphasia, AD = Alzheimer disease. *= Kruskal-Wallis test, ** = Pearson Chi-square test.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2. CDR-FTLD scores (means and standard deviations) according to FTD-
FRS severity stages in the total sample (N= 70). 
FTD-FRS 
Time 
CDR-FTLD 
n Mean Std.Dev. Std.Error Minimum Median Maximum 
Very Mild Baseline 3 5.70 2.59 1.16 3.00 5.00 9.50 
  Follow-up 3 6.10 2.48 1.11 3.00 6.50 9.50 
Mild Baseline 5 8.83 4.31 2.49 5.00 8.00 13.50 
  Follow-up 5 9.00 4.58 2.65 5.00 8.00 14.00 
Moderate Baseline 18 7.83 3.39 0.80 3.50 7.50 16.00 
  Follow-up 18 8.39 3.11 0.73 5.00 8.00 16.00 
Severe Baseline 32 8.69 4.11 0.73 2.50 7.75 19.00 
  Follow-up 32 8.77 3.62 0.64 3.50 7.75 19.00 
Very Severe Baseline 7 9.29 2.84 1.07 5.50 10.50 13.00 
  Follow-up 7 10.21 2.81 1,06 6.00 10.50 14.00 
Profound Baseline 5 10.40 2.16 0.97 7.50 10.00 13.00 
  Follow-up 5 10.80 2.66 1.19 7.50 10.00 14.00 
Note. FTD-FRS, frontotemporal dementia rating scale; CDR-FTLD=clinical dementia rating 
scale for frontotemporal lobar degeneration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 3. CDR-FTLD scores (means and standard deviations) according to FTD-
FRS severity stages in the bvFTD group (N=31) 
FTD-FRS 
Time 
CDR-FTLD 
n Mean Std.Dev. Std.Error Minimum Median Maximum 
Very Mild Baseline 1 8.00 - - 8.00 8.00 8.00 
  Follow-up 1 8.00 - - 8.00 8.00 8.00 
Mild Baseline - - - - - - - 
  Follow-up - - - - - - - 
Moderate Baseline 7 8.03 3.58 0.89 2.50 7.75 15.00 
  Follow-up 7 8.19 3.26 0.82 3.50 7.75 15.00 
Severe Baseline 16 9.64 4.23 1.60 3.50 9.50 16.00 
  Follow-up 16 10.21 3.86 1.46 5.50 9.50 16.00 
Very Severe Baseline 5 9.30 2.66 1.19 5.50 9.00 11.00 
  Follow-up 5 9.60 3.07 1.37 6.00 10.00 14.00 
Profound Baseline 2 10.25 3.89 2.75 7.50 10.25 13.00 
  Follow-up 2 10.25 3.89 2.75 7.50 10.25 13.00 
Note. FTD-FRS, frontotemporal dementia rating scale; CDR-FTLD=clinical dementia rating 
scale for frontotemporal lobar degeneration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 4. CDR-FTLD scores (means and standard deviations) according to FTD-
FRS severity stages in the PPA group (N= 12). 
FTD-FRS 
Time 
CDR-FTLD 
n Mean Std.Dev. Std.Error Minimum Median Maximum 
Very Mild Baseline 2 7.17 2.52 1.45 4.50 7.50 9.50 
  Follow-up 2 7.67 2.36 1.36 5.00 8.50 9.50 
Mild Baseline - - - - - - - 
  Follow-up - - - - - - - 
Moderate Baseline  3 9.25 6.01 4.25 5.00 9.25 13.50 
  Follow-up 3 9.50 6.36 4.50 5.00 9.50 14.00 
Severe Baseline 6 11.58 4.62 1.89 6.50 10.25 19.00 
  Follow-up 6 12.08 4.13 1.69 8.00 10.50 19.00 
Very Severe Baseline - - - - - - - 
  Follow-up - - - - - - - 
Profound Baseline 1 10.00 - - 10.00 10.00 10.00 
  Follow-up 1 10.00 - - 10.00 10.00 10.00 
Note. FTD-FRS, frontotemporal dementia rating scale; CDR-FTLD=clinical dementia rating 
scale for frontotemporal lobar degeneration 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 5.  CDR-FTLD scores (means and standard deviations) according to FTD-
FRS severity stages in the AD group (N=27). 
FTD-FRS 
Time 
CDR-FTLD 
N Mean Std.Dev. Std.Error Minimum Median Maximum 
Very Mild Baseline - - - - - - - 
  Follow-up - - - - - - - 
Mild Baseline 5 5.70 2.59 1.16 3.00 5.00 9.50 
  Follow-up 5 6.10 2.48 1.11 3.00 6.50 9.50 
Moderate Baseline 8 6.50 2.30 0.81 4.00 6.00 10.00 
  Follow-up 8 7.06 1.90 0.67 5.00 6.50 10.00 
Severe Baseline 10 6.40 3.51 1.11 3.50 5.25 13.00 
  Follow-up 10 7.70 2.97 0.94 4.00 6.75 13.00 
Very Severe Baseline 2 11.75 1.77 1.25 10.50 11.75 13.00 
  Follow-up 2 11.75 1.77 1.25 10.50 11.75 13.00 
Profound Baseline 2 10.75 1.77 1.25 9.50 10.75 12.00 
  Follow-up 2 11.75 3.18 2.25 9.50 11.75 14.00 
Note. FTD-FRS, frontotemporal dementia rating scale; CDR-FTLD=clinical dementia rating 
scale for frontotemporal lobar degeneration 
 
 
 
 
 
